Scope of the Study
Influenza is a viral infection that attacks the respiratory system involving the nose, throat and lungs. It is commonly called as the flu, but it is not as same as stomach flu viruses that cause diarrhea and vomiting. It mainly attacks young children, older adults, pregnant women and people with chronic disease or a weak immune system. Its symptoms include fever, chills, muscle aches, cough, congestion, runny nose, headaches and fatigue. The treatment of influenza includes antiviral medication, such as oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) or baloxavir (Xofluza). Most circulating strains of influenza have become resistant to drugs such as amantadine and rimantadine (Flumadine), which are older antiviral drugs that are no longer recommended.
The market study is being classified by Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil and Others) and major geographies with country level break-up.
AstraZeneca Plc (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States), Daiichi Sankyo Company, Limited (Japan), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Mylan N.V. (United States), Natco Pharma Limited (India), Novartis AG (Switzerland), Sanofi S.A. (France) and Teva Pharmaceutical Industries Limited (Israel) are some of the key players profiled in the study.
Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Influenza Treatment market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Influenza Treatment market by Type, Application and Region.
On the basis of geography, the market of Influenza Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Adoption of Influenza Vaccine
- Increased Prevalence of Influenza
- Rising Regulatory Approvals
- Increase in the Healthcare Expenditure
- Growing Focus on Preventive Healthcare
- Resistance of Influenza Strains to Drugs
- Growth in the Healthcare Industry
- Technological Advancements in the Medical Science
- High Growth Potential in Developing Regions
- Lack of Health Care Infrastructure in Some Regions
In October 2019, Roche has announced FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications.
Key Target AudienceInfluenza Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase